Ambrx Biopharma Inc
AMAM
AMAM was delisted on the 6th of March, 2024.
42 hedge funds and large institutions have $789M invested in Ambrx Biopharma Inc in 2023 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 6 closing their positions.
200% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 6
139% more capital invested
Capital invested by funds: $331M → $789M (+$458M)
63% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 8
40% more funds holding
Funds holding: 30 → 42 (+12)
24% more call options, than puts
Call options by funds: $4.87M | Put options by funds: $3.92M
11.89% more ownership
Funds ownership: 67.15% → 79.04% (+12%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$67.7M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$24M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
+$20.8M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$14M |
| 5 |
Holocene Advisors
New York
|
+$11.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$20.5M |
| 2 |
VA
VR Adviser
New York
|
-$10.2M |
| 3 |
FI
Fosun International
Hong Kong,
China
|
-$2.22M |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$1.43M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$715K |
AMAM Hedge Fund Activity: Q2 2023 in Review
42 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Ambrx Biopharma Inc (AMAM) for Q2 2023, worth a combined $789M — up 139% from $331M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new AMAM positions and 6 closed out — a net gain of 12 holders — while 13 added to existing stakes and 8 trimmed.
The largest buyer was Darwin Global Management, adding an estimated $67.7M. The largest seller was Commodore Capital, cutting an estimated $20.5M.
- 42 institutional investors held Ambrx Biopharma Inc (AMAM) as of Q2 2023, up from 30 in Q1 2023.
- Funds reported $789M of Ambrx Biopharma Inc stock for Q2 2023, up 139% quarter-over-quarter.
- 18 funds opened new Ambrx Biopharma Inc positions in Q2 2023 and 6 closed out, a net change of +12 holders.
- The largest Ambrx Biopharma Inc buyer in Q2 2023 was Darwin Global Management, an estimated $67.7M added.
- The largest Ambrx Biopharma Inc seller in Q2 2023 was Commodore Capital, an estimated $20.5M sold.
Based on aggregated 13F filings for Q2 2023.